Rifaximin and the DCA–serotonin axis in cirrhotic portal hypertension: how much of the benefit is bile-acid specific?
- 20 June 2026
- journal article
- Published by Elsevier in Journal of Hepatology
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Rifaximin ameliorates cirrhotic portal hypertension through suppression of microbiome-derived deoxycholic acidJournal of Hepatology, 2026
- Targeting the gut-liver axis in liver diseaseJournal of Hepatology, 2017
- Animal models of chronic liver diseasesAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2013
- Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR AntagonistCell Metabolism, 2013